0001803901Q1false--12-310001803901us-gaap:SellingAndMarketingExpenseMember2022-01-012022-03-310001803901srt:MaximumMembertalk:TwoThousandAndTwentyOneEmployeeStockPurchasePlanMemberus-gaap:CommonStockMember2022-03-310001803901talk:ConsumerMember2022-01-012022-03-310001803901talk:HealthPlansAndEapCustomersMember2022-03-310001803901talk:PrivatePlacementWarrantMember2022-03-310001803901us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-03-310001803901talk:CommercialMember2022-01-012022-03-310001803901us-gaap:CommonStockMembertalk:TwoThousandAndTwentyOneIncentiveAwardPlanMember2022-03-3100018039012021-12-310001803901us-gaap:ConvertiblePreferredStockMember2021-03-310001803901talk:PrivatePlacementWarrantMember2022-01-012022-03-310001803901talk:WarrantsToCommonStockMember2021-01-012021-03-310001803901us-gaap:RetainedEarningsMember2021-01-012021-03-3100018039012021-06-012021-06-300001803901us-gaap:CommonStockMember2022-01-012022-03-310001803901us-gaap:SellingAndMarketingExpenseMember2021-01-012021-03-310001803901us-gaap:CommonStockMember2021-01-012021-03-310001803901us-gaap:EmployeeStockOptionMember2022-01-012022-03-310001803901us-gaap:WarrantMember2022-01-012022-03-3100018039012021-01-012021-12-310001803901talk:TwoThousandAndTwentyOneIncentiveAwardPlanMember2022-03-310001803901talk:PrivatePlacementWarrantMember2021-12-310001803901us-gaap:FairValueInputsLevel3Membertalk:PrivatePlacementWarrantMemberus-gaap:FairValueMeasurementsRecurringMember2022-03-310001803901us-gaap:EmployeeStockOptionMember2021-01-012021-03-310001803901us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-03-310001803901us-gaap:CommonStockMembertalk:TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember2022-03-3100018039012021-03-310001803901us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-310001803901us-gaap:CommonStockMember2022-01-012022-03-310001803901talk:PublicWarrantMember2022-01-012022-03-310001803901us-gaap:RetainedEarningsMember2021-12-310001803901us-gaap:EmployeeStockOptionMember2021-01-012021-03-310001803901us-gaap:AdditionalPaidInCapitalMember2021-12-310001803901us-gaap:RetainedEarningsMember2022-03-310001803901us-gaap:CommonStockMember2022-03-310001803901us-gaap:RestrictedStockUnitsRSUMember2022-03-310001803901talk:ClinicalOperationsMember2022-01-012022-03-310001803901us-gaap:ConvertiblePreferredStockMember2022-03-310001803901srt:MaximumMembertalk:TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember2022-01-012022-03-310001803901us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310001803901us-gaap:ConvertiblePreferredStockMember2021-12-310001803901us-gaap:RetainedEarningsMember2021-03-3100018039012022-03-310001803901us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-03-310001803901us-gaap:RetainedEarningsMember2022-01-012022-03-310001803901us-gaap:FairValueInputsLevel3Membertalk:PrivatePlacementWarrantMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001803901us-gaap:GeneralAndAdministrativeExpenseMember2021-01-012021-03-310001803901talk:PrivatePlacementWarrantMember2021-01-012021-12-310001803901talk:ConsumerMember2021-01-012021-03-310001803901srt:MaximumMemberus-gaap:CommonStockMembertalk:TwoThousandAndTwentyOneIncentiveAwardPlanMember2022-01-012022-03-310001803901us-gaap:CommonStockMember2021-03-3100018039012020-12-310001803901us-gaap:CommonStockMember2021-12-310001803901us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-03-3100018039012021-01-012021-03-310001803901talk:ClinicalOperationsMember2021-01-012021-03-310001803901us-gaap:ConvertiblePreferredStockMember2020-12-310001803901talk:WarrantToPurchaseSeriesDConvertiblePreferredStockMember2021-01-012021-03-310001803901us-gaap:RestrictedStockUnitsRSUMember2021-12-310001803901us-gaap:ConvertiblePreferredStockMember2021-01-012021-03-310001803901talk:PrivatePlacementWarrantMember2022-01-012022-03-310001803901us-gaap:RetainedEarningsMember2020-12-3100018039012021-06-220001803901us-gaap:CommonStockMember2020-12-310001803901us-gaap:AdditionalPaidInCapitalMember2021-03-310001803901us-gaap:AdditionalPaidInCapitalMember2022-03-3100018039012022-01-012022-03-310001803901us-gaap:AdditionalPaidInCapitalMember2020-12-310001803901talk:CommercialMember2021-01-012021-03-310001803901us-gaap:EmployeeStockOptionMember2022-01-012022-03-3100018039012022-05-02xbrli:pureiso4217:USDxbrli:sharesxbrli:sharesiso4217:USD

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 10-Q**

**(Mark One)**

|  |  |
| --- | --- |
|  |  |
| **☒** | **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934** |

**For the quarterly period ended March 31, 2022**

**OR**

|  |  |
| --- | --- |
|  |  |
| **☐** | **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934** |

**For the transition period from to**

**Commission File Number: 001-39314**

**TALKSPACE, INC.**

**(Exact Name of Registrant as Specified in its Charter)**

|  |  |
| --- | --- |
|  |  |
| **Delaware** | **84-4636604** |
| **(State or other jurisdiction of**  **incorporation or organization)** | **(I.R.S. Employer Identification No.)** |
| **Not applicable** | **Not applicable** |
| **(Address of principal executive offices)** | **(Zip Code)** |

**(212) 284-7206**

**(Registrant’s telephone number, including area code)**

**N/A**

**(Former name, former address and former fiscal year, if changed since last report)**

Securities registered pursuant to Section 12(b) of the Act:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  |  |  |  |  |
| **Title of each class** |  | **Trading**  **Symbol(s)** |  | **Name of each exchange on which registered** |
| Common stock, par value $0.0001 per share |  | TALK |  | Nasdaq Stock Market |
| Warrants to purchase common stock |  | TALKW |  | Nasdaq Stock Market |

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |
| Large accelerated filer |  | ☒ |  | Accelerated filer |  | ☐ |
|  |  | |  | |  | |
| Non-accelerated filer |  | ☐ |  | Smaller reporting company |  | ☐ |
|  |  |  |  |  |  |  |
| Emerging growth company |  | ☐ |  |  |  |  |

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of May 2, 2022, the registrant had 155,116,870 shares of common stock, $0.0001 par value per share, outstanding.

**Table of Contents**

|  |  |  |
| --- | --- | --- |
|  |  |  |
|  |  | **Page** |
| **PART I.** | **FINANCIAL INFORMATION** |  |
| Item 1. | [Financial Statements (Unaudited)](#i_item1) | 6 |
|  | [Condensed Consolidated Balance Sheets as of March 31, 2022 (unaudited) and December 31, 2021](#balance_sheet) | 6 |
|  | [Condensed Consolidated Statements of Operations (unaudited) for the three months ended March 31, 2022 and 2021](#statements_operations) | 7 |
|  | [Condensed Consolidated Statements of Stockholder’s Equity (Deficit) (unaudited) for the three months ended March 31, 2022 and 2021](#statements_equity) | 8 |
|  | [Condensed Consolidated Statements of Cash Flows (unaudited) for the three months ended March 31, 2022 and 2021](#statements_cash_flows) | 9 |
|  | [Notes to Unaudited Condensed Consolidated Financial Statements](#notes_financial_statements) | 10 |
| Item 2. | [Management’s Discussion and Analysis of Financial Condition and Results of Operations](#i_item2) | 18 |
| Item 3. | [Quantitative and Qualitative Disclosures About Market Risk](#i_item3) | 26 |
| Item 4. | [Controls and Procedures](#i_item4) | 27 |
| **PART II.** | **OTHER INFORMATION** |  |
| Item 1. | [Legal Proceedings](#ii_item1) | 30 |
| Item 1A. | [Risk Factors](#item_1a_risk_factors) | 30 |
| Item 2. | [Unregistered Sales of Equity Securities and Use of Proceeds](#ii_item2) | 31 |
| Item 3. | [Defaults Upon Senior Securities](#ii_item3) | 31 |
| Item 4. | [Mine Safety Disclosures](#ii_item4) | 31 |
| Item 5. | [Other Information](#ii_item5) | 31 |
| Item 6. | [Exhibits](#ii_item6) | 32 |
| [Signatures](#signatures) | | 33 |

2

**basis of presentation**

As used in this Quarterly Report, unless the context otherwise requires, references to:

•

“***2021 Plan***” are to the Talkspace, Inc. 2021 Incentive Award Plan;

•

“***Business Combination***” are to, together, (i) the First Merger and (ii) the Second Merger;

•

“***2021 ESPP”*** are to the Talkspace, Inc. 2021 Employee Stock Purchase Plan;

•

“***Exchange Act***” are to the Securities Exchange Act of 1934, as amended;

•

“***First Merger***” are to the merger of First Merger Sub with and into Old Talkspace;

•

“***First Merger Sub***” are to Tailwind Merger Sub I, Inc.;

•

“***HEC***” are to Hudson Executive Investment Corp., a Delaware corporation;

•

“***HEC Forward Purchase Agreement***” are to the forward purchase agreement, entered into as of June 8, 2020, by and between HEC and HEC Fund, as amended by that certain First Amendment to Forward Purchase Agreement, dated January 12, 2021;

•

“***HEC Fund***” are to HEC Master Fund LP, a Delaware limited partnership;

•

“***HEC IPO***” are to the initial public offering by HEC which closed on June 11, 2020;

•

“***Merger Agreement***” are to that certain Agreement and Plan of Merger, dated as of January 12, 2021, by and among HEC, Old Talkspace, First Merger Sub and Second Merger Sub;

•

“***Old Talkspace***” are to Groop Internet Platform, Inc. (d/b/a “Talkspace”), a Delaware corporation;

•

“***private placement warrants***” are to the warrants issued by HEC to the Sponsor in a private placement simultaneously with the closing of the HEC IPO and the warrants originally sold as part of the units in the HEC Forward Purchase;

•

“***public warrants***” are to the warrants originally sold as part of the units in the HEC IPO (whether they were purchased in the HEC IPO or thereafter in the open market);

•

“***SEC***” are to the United States Securities and Exchange Commission;

•

“***Second Merger Sub***” are to Tailwind Merger Sub II, LLC;

•

“***Sponsor***” are to HEC Sponsor LLC, a Delaware limited liability company;

•

“***Warrant Agreement***” are to that certain Warrant Agreement, dated as of June 8, 2020, by and between HEC and Continental Stock Transfer & Trust Company; and

•

“***warrants***” are to the public warrants and the private placement warrants.

3

**FORWARD-LOOKING STATEMENTS**

This Quarterly Report on Form 10-Q (the “Quarterly Report”) contains forward-looking statements. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements other than statements of historical facts contained in this Quarterly Report may be forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “targets,” “projects,” “contemplates,” “believes,” “estimates,” “forecasts,” “predicts,” “potential” or “continue” or the negative of these terms or other similar expressions. Forward-looking statements contained in this Quarterly Report include, but are not limited to, statements regarding our future results of operations and financial position, industry and business trends, stock-based compensation, revenue recognition, business strategy, plans and market growth.

The forward-looking statements in this Quarterly Report are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to: we have a history of losses, which we expect to continue, and we may never achieve or sustain profitability; our business and the markets we operate in are new and rapidly evolving which makes it difficult to evaluate our future prospects and the risks and challenges we may encounter; we may not grow at the rates we historically have achieved or at all; the virtual behavioral health market is immature and volatile, and if it does not develop, if it develops more slowly than we expect, if it encounters negative publicity or if our services are not competitive, the growth of our business will be harmed; the outbreak of the novel coronavirus (COVID-19) and its impact on business and economic conditions could adversely affect our business, results of operations and financial condition, and the extent and duration of those effects will be uncertain; we operate in a competitive industry, and if we are not able to compete effectively, our business, financial condition and results of operations will be harmed; if growth in the number of clients and members or providers on our platform decreases, or the number of products or services that we are able to sell to our clients and members decreases, due to legal, economic or business developments, our business, financial condition and results of operations will be harmed; we may be unsuccessful in achieving broad market education and changing consumer purchasing habits; our growth depends in part on the success of our strategic relationships with third parties that we provide services to; our virtual behavioral healthcare strategies depend on our ability to maintain and expand our network of therapists, psychiatrists and other providers; developments affecting spending by the healthcare industry could adversely affect our business; our business could be adversely affected by legal challenges to our business model or by actions restricting our ability to provide the full range of our services in certain jurisdictions; we are dependent on our relationships with affiliated professional entities, which we do not own, to provide physician and other professional services, and our business, financial condition and our ability to operate in certain jurisdictions would be adversely affected if those relationships were disrupted or if our arrangements with our providers or clients are found to violate state laws prohibiting the corporate practice of medicine or fee splitting; the impact on us of recent healthcare legislation and other changes in the healthcare industry and in healthcare spending is currently unknown, but may adversely affect our business, financial condition and results of operations; changes in consumer sentiment or laws, rules or regulations regarding the use of cookies and other tracking technologies and other privacy matters could have a material adverse effect on our ability to generate net revenues and could adversely affect our ability to collect proprietary data on consumer behavior; our use and disclosure of personal information, including PHI, personal data, and other health information, is subject to state, federal or other privacy and security regulations; any failure to protect, enforce or defend our intellectual property rights could impair our ability to protect our technology and our brand; legal proceedings could cause us to incur unforeseen expenses and could occupy a significant amount of our management’s time and attention; and the other important factors discussed in Part I, Item 1A, “Risk Factors” of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and described from time to time in our future reports filed with the SEC. The forward-looking statements in this Quarterly Report are based upon information available to us as of the date of this Quarterly Report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely upon these statements.

4

You should read this Quarterly Report and the risk factors discussed in Part I, Item 1A, “Risk Factors” of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 with the understanding that our actual future results, levels of activity, performance and achievements may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements. These forward-looking statements speak only as of the date of this Quarterly Report. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained in this Quarterly Report, whether as a result of any new information, future events or otherwise.

5

**PART I—FINANCIAL INFORMATION**

**Item 1. Financial Statements.**

**TALKSPACE, INC.**

**CONDENSED CONSOLIDATED BALANCE SHEETS**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |
|  |  | **March 31, 2022** | |  |  | **December 31, 2021** | |  |
| *(U.S. dollars in thousands, except share and per share data)* |  | (Unaudited) | |  |  |  | |  |
| ASSETS |  |  | |  |  | ﻿ | |  |
| CURRENT ASSETS: |  | ﻿ | |  |  | ﻿ | |  |
| Cash and cash equivalents |  | $ | 184,127 |  |  | $ | 198,256 |  |
| Accounts receivable, net of reserves of $4,706 and $4,918 as of March 31, 2022 and December 31, 2021, respectively |  |  | 6,312 |  |  |  | 5,512 |  |
| Other current assets |  |  | 5,039 |  |  |  | 9,562 |  |
| Total current assets |  |  | 195,478 |  |  |  | 213,330 |  |
| Property and equipment, net |  |  | 633 |  |  |  | 624 |  |
| Intangible assets, net |  |  | 3,086 |  |  |  | 3,436 |  |
| Goodwill |  |  | 6,134 |  |  |  | 6,134 |  |
| Other long-term assets |  |  | 82 |  |  |  | 82 |  |
| Total assets |  | $ | 205,413 |  |  | $ | 223,606 |  |
| LIABILITIES AND STOCKHOLDERS’ EQUITY |  | ﻿ | |  |  | ﻿ | |  |
| CURRENT LIABILITIES: |  | ﻿ | |  |  | ﻿ | |  |
| Accounts payable |  | $ | 9,490 |  |  | $ | 7,429 |  |
| Deferred revenues |  |  | 6,026 |  |  |  | 7,186 |  |
| Accrued expenses and other current liabilities |  |  | 10,234 |  |  |  | 12,562 |  |
| Total current liabilities |  |  | 25,750 |  |  |  | 27,177 |  |
| Warrant liabilities |  |  | 3,195 |  |  |  | 4,070 |  |
| Other long-term liabilities |  |  | 191 |  |  |  | 86 |  |
| Total liabilities |  |  | 29,136 |  |  |  | 31,333 |  |
| Commitments and contingencies (Note 5) |  |  | |  |  |  | |  |
| STOCKHOLDERS’ EQUITY: |  | ﻿ | |  |  | ﻿ | |  |
| Common stock of $0.0001 par value — Authorized: 1,000,000,000 shares at March 31, 2022 and December 31, 2021; Issued and outstanding: 155,104,655 and 152,862,447 shares at March 31, 2022 and December 31, 2021, respectively |  |  | 15 |  |  |  | 15 |  |
| Additional paid-in capital |  |  | 368,152 |  |  |  | 363,788 |  |
| Accumulated deficit |  |  | (191,890 | ) |  |  | (171,530 | ) |
| Total stockholders’ equity |  |  | 176,277 |  |  |  | 192,273 |  |
| Total liabilities and stockholders’ equity |  | $ | 205,413 |  |  | $ | 223,606 |  |

The accompanying notes are an integral part of the condensed consolidated financial statements.

6

**TALKSPACE, INC.**

**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**

**(Unaudited)**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |
|  |  | **Three Months Ended** | | | | | |  |
|  |  | **March 31,** | | | | | |  |
| *(U.S. dollars in thousands, except share and per share data)* |  | **2022** | |  |  | **2021** | |  |
| Revenues |  | $ | 30,150 |  |  | $ | 27,157 |  |
| Cost of revenues |  |  | 15,129 |  |  |  | 9,814 |  |
| Gross profit |  |  | 15,021 |  |  |  | 17,343 |  |
| Operating expenses: |  |  | |  |  |  | |  |
| Research and development, net |  |  | 5,035 |  |  |  | 2,964 |  |
| Clinical operations |  |  | 1,776 |  |  |  | 2,077 |  |
| Sales and marketing |  |  | 21,408 |  |  |  | 22,251 |  |
| General and administrative |  |  | 8,010 |  |  |  | 2,608 |  |
| Total operating expenses |  |  | 36,229 |  |  |  | 29,900 |  |
| Operating loss |  |  | 21,208 |  |  |  | 12,557 |  |
| Financial (income) expense, net |  |  | (869 | ) |  |  | 173 |  |
| Loss before taxes on income |  |  | 20,339 |  |  |  | 12,730 |  |
| Taxes on income |  |  | 21 |  |  |  | 8 |  |
| Net loss |  | $ | 20,360 |  |  | $ | 12,738 |  |
| Net loss per share (1): |  |  | |  |  |  | |  |
| Basic and diluted net loss per share |  | $ | 0.13 |  |  | $ | 0.93 |  |
| Weighted average number of common shares (1): |  |  | |  |  |  | |  |
| Weighted average number of common shares used in computing basic and diluted net loss per share: |  |  | 154,083,443 |  |  |  | 13,762,205 |  |

(1) Prior period results have been adjusted to reflect the exchange of Old Talkspace’s common stock for Talkspace’s common stock at an exchange ratio of approximately 1.134140 in June 2021 as a result of the Business Combination.

The accompanying notes are an integral part of the condensed consolidated financial statements.

7

**TALKSPACE, INC.**

**CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (DEFICIT)**

**(Unaudited)**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  | |  |  |  | |  |  |  | |  |  |  | |  |  |  | |  |  |  | |  |  |  | |  |
| *(U.S. dollars in thousands, except share and per share data)* |  | **Convertible Preferred Stock** | | | | | |  |  | **Common Stock** | | | | | |  |  |  | |  |  |  | |  |  |  | |  |
| **Three Months Ended March 31, 2022** |  | **Number of Shares Outstanding** | |  |  | **Amount** | |  |  | **Number of Shares Outstanding** | |  |  | **Amount** | |  |  | **Additional paid-in capital** | |  |  | **Accumulated deficit** | |  |  | **Total** | |  |
| Balance as of December 31, 2021 |  |  | — |  |  | $ | — |  |  |  | 152,862,447 |  |  | $ | 15 |  |  | $ | 363,788 |  |  | $ | (171,530 | ) |  | $ | 192,273 |  |
| Exercise of stock options |  |  | — |  |  |  | — |  |  |  | 2,164,870 |  |  | \*) | |  |  |  | 2,063 |  |  |  | — |  |  |  | 2,063 |  |
| Restricted stock units vested, net of tax |  |  | — |  |  |  | — |  |  |  | 77,338 |  |  | \*) | |  |  |  | (67 | ) |  |  | — |  |  |  | (67 | ) |
| Stock-based compensation |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 2,368 |  |  |  | — |  |  |  | 2,368 |  |
| Net loss |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (20,360 | ) |  |  | (20,360 | ) |
| Balance as of March 31, 2022 |  |  | — |  |  | $ | — |  |  |  | 155,104,655 |  |  | $ | 15 |  |  | $ | 368,152 |  |  | $ | (191,890 | ) |  | $ | 176,277 |  |
|  |  |  | |  |  |  | |  |  |  | |  |  |  | |  |  |  | |  |  |  | |  |  |  | |  |
|  |  | **Convertible Preferred Stock (1)** | | | | | |  |  | **Common Stock (1)** | | | | | |  |  |  | |  |  |  | |  |  |  | |  |
| **Three Months Ended March 31, 2021** |  | **Number of Shares Outstanding** | |  |  | **Amount** | |  |  | **Number of Shares Outstanding** | |  |  | **Amount** | |  |  | **Additional paid-in capital (1)** | |  |  | **Accumulated deficit** | |  |  | **Total** | |  |
| Balance as of December 31, 2020 |  |  | 94,582,550 |  |  | $ | 111,282 |  |  |  | 13,413,431 |  |  | $ | 1 |  |  | $ | 9,889 |  |  | $ | (108,788 | ) |  | $ | (98,898 | ) |
| Exercise of stock options |  |  | — |  |  |  | — |  |  |  | 684,923 |  |  | \*) | |  |  |  | 797 |  |  |  | — |  |  |  | 797 |  |
| Stock-based compensation |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 1,513 |  |  |  | — |  |  |  | 1,513 |  |
| Issuance of warrants |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 125 |  |  |  | — |  |  |  | 125 |  |
| Net loss |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (12,738 | ) |  |  | (12,738 | ) |
| Balance as of March 31, 2021 |  |  | 94,582,550 |  |  | $ | 111,282 |  |  |  | 14,098,354 |  |  | $ | 1 |  |  | $ | 12,324 |  |  | $ | (121,526 | ) |  | $ | (109,201 | ) |

\*) Represents an amount lower than $1

(1) Prior period results have been adjusted to reflect the exchange of Old Talkspace’s common stock for Talkspace’s common stock at an exchange ratio of approximately 1.134140 in June 2021 as a result of the Business Combination.

The accompanying notes are an integral part of the condensed consolidated financial statements.

8

**TALKSPACE, INC.**

**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**

**(Unaudited)**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |
|  |  | **Three Months Ended March 31,** | | | | | |  |
| *(U.S. dollars in thousands)* |  | **2022** | |  |  | **2021** | |  |
| **Cash flows from operating activities:** |  |  | |  |  |  | |  |
| Net loss |  | $ | (20,360 | ) |  | $ | (12,738 | ) |
| Adjustments to reconcile net loss to net cash used in operating activities: |  |  | |  |  |  | |  |
| Depreciation and amortization |  |  | 429 |  |  |  | 462 |  |
| Stock-based compensation |  |  | 2,368 |  |  |  | 1,513 |  |
| Warrant change in fair value |  |  | (875 | ) |  |  | 165 |  |
| Increase in accounts receivable, net |  |  | (800 | ) |  |  | (1,666 | ) |
| Decrease (increase) in other current assets |  |  | 4,923 |  |  |  | (1,076 | ) |
| Increase in accounts payable |  |  | 2,061 |  |  |  | 7,030 |  |
| (Decrease) increase in deferred revenues |  |  | (1,160 | ) |  |  | 2,878 |  |
| Decrease in accrued expenses and other current liabilities |  |  | (1,837 | ) |  |  | (447 | ) |
| Increase in other long-term liabilities |  |  | 105 |  |  |  | — |  |
| Net cash used in operating activities |  |  | (15,146 | ) |  |  | (3,879 | ) |
| **Cash flows from investing activities:** |  |  | |  |  |  | |  |
| Purchase of property and equipment |  |  | (88 | ) |  |  | (319 | ) |
| Net cash used in investing activities |  |  | (88 | ) |  |  | (319 | ) |
| **Cash flows from financing activities:** |  |  | |  |  |  | |  |
| Payment of deferred issuance costs |  |  | — |  |  |  | (75 | ) |
| Proceeds from exercise of stock options |  |  | 2,063 |  |  |  | 797 |  |
| Payments for employee taxes withheld related to vested stock-based awards |  |  | (558 | ) |  |  | — |  |
| Net cash provided by financing activities |  |  | 1,505 |  |  |  | 722 |  |
| Net decrease in cash and cash equivalents |  |  | (13,729 | ) |  |  | (3,476 | ) |
| Cash and cash equivalents at the beginning of the period |  |  | 198,256 |  |  |  | 13,248 |  |
| Cash and cash equivalents at the end of the period (1) |  | $ | 184,527 |  |  | $ | 9,772 |  |
| Supplemental cash flow data: |  |  | |  |  |  | |  |
| Cash paid during the period for interest |  | $ | 12 |  |  | $ | 5 |  |
| Cash paid during the period for income taxes |  | $ | 174 |  |  | $ | — |  |
| Non-cash financing activity: |  |  | |  |  |  | |  |
| Deferred issuance costs |  | $ | — |  |  | $ | 2,673 |  |
| Issuance of warrant and other costs related to the Credit Agreement |  | $ | — |  |  | $ | 175 |  |

(1) As of March 31, 2022, amount includes restricted cash of $0.4 million maintained in a short-term certificate of deposit account and included within other current assets in the condensed consolidated balance sheet.

The accompanying notes are an integral part of the condensed consolidated financial statements.

9

**TALKSPACE, INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(Unaudited)**

**NOTE 1. DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS**

Talkspace, Inc. (together with its consolidated subsidiaries, the “Company” or “Talkspace”) is a leading behavioral healthcare company enabled by a purpose-built technology platform. Talkspace provides individuals and licensed therapists, psychologists and psychiatrists with an online platform for one-on-one therapy delivered via messaging, audio and video. Talkspace was originally incorporated as Hudson Executive Investment Corp. (“HEC”). In connection with the Business Combination completed in June 2021, HEC filed the Certificate of Incorporation and changed its name to “Talkspace, Inc.”.

***Operating Segments***

The Company operates its business as a single segment and as one reporting unit, which is how our chief operating decision maker (who is our interim chief executive officer) reviews financial performance and allocates resources.

**NOTE 2. SIGNIFICANT ACCOUNTING POLICIES**

*Basis of presentation*

The unaudited condensed consolidated financial statements and accompanying notes have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). In management’s opinion, the unaudited condensed consolidated financial statements reflect all adjustments of a normal recurring nature that are necessary for a fair presentation of the results for the interim periods presented. The Company’s interim period results do not necessarily indicate the results that may be expected for any other interim period or for the full fiscal year.

The significant accounting policies applied in the annual consolidated financial statements of the Company as of December 31, 2021, have been applied consistently in these unaudited condensed consolidated financial statements, unless otherwise stated. These interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements as of and for the year ended December 31, 2021 included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.

*Use of estimates*

The preparation of consolidated financial statements, in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company evaluates its assumptions on an ongoing basis. The Company’s management believes that the estimates, judgment, and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the condensed consolidated financial statements, and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.

*Recently Issued and Adopted Accounting Pronouncements*

In November 2021, the Financial Accounting Standards Board (“FASB”) issued ASU 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance, which requires entities to disclose information about certain types of government assistance they receive in the notes to the financial statements. Entities are required to provide the new disclosures prospectively for all transactions with a government entity that are accounted for under either a grant or a contribution accounting model and are reflected in the financial statements at the date of initially applying the new amendments, and to new transactions entered into after that date. Retrospective application of the guidance is permitted. The amendments in this ASU are effective for all entities within their scope for financial statements issued for annual periods beginning after December 15, 2021. The Company adopted this guidance on January 1, 2022 and the adoption did not have a significant impact on its condensed consolidated financial statements or related disclosures.

In May 2021, the FASB issued ASU 2021-04—Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options, which clarifies and reduces diversity in accounting for modifications or exchanges of freestanding

10

equity-written call options that remain equity classified after modifications or exchanges based on the substance of the transactions. The amendments in this ASU are effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. The Company adopted this guidance on January 1, 2022 and the adoption did not have an impact on its condensed consolidated financial statements or related disclosures.

In August 2020, the FASB issued ASU 2020-06—Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer's Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. The amendments in this ASU are effective for public entities excluding entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. The Company adopted this guidance on January 1, 2022 and the adoption did not have an impact on its condensed consolidated financial statements or related disclosures.

**NOTE 3. REVENUE RECOGNITION**

The Company is operating a virtual behavioral healthcare business that connects individuals and licensed therapists, psychologists and psychiatrists with an online platform for one-on-one therapy delivered via messaging, audio and video. Individuals access the Company’s services through the Company’s website or mobile app. The Company generates revenues from the sale of monthly, quarterly, bi-annual and annual membership subscriptions to its therapy platform as well as supplementary a la carte offerings, payments from members and their respective insurance companies and annually contracted platform access fees from enterprise clients for the delivery of therapy services to their members or employees.

The Company provides these services directly to individuals through a subscription plan. The Company also contracts with health plans and other enterprises to provide its services to individuals who are qualified to receive access to the Company’s services through the Company’s commercial arrangements.

The following table presents the Company’s revenues disaggregated by revenue source:

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |
|  |  | **Three Months Ended March 31,** | | | | | |  |
| *(in thousands)* |  | **2022** | |  |  | **2021** | |  |
| Revenues from sales to unaffiliated customers: |  | ﻿ | |  | ﻿ |  | |  |
| Consumers |  | $ | 17,260 |  |  | $ | 18,564 |  |
| Commercial |  |  | 12,890 |  |  |  | 8,593 |  |
| Total |  | $ | 30,150 |  |  | $ | 27,157 |  |

*Accounts Receivable and Revenue Reserves*

Revenue reserves are deducted from accounts receivable to present the net amount expected to be collected. As of March 31, 2022, revenue reserves mainly relate to allowances for accounts receivable balances from health insurance and EAP organizations. During the three months ended March 31, 2022, the Company recorded an increase in revenue reserves of $1.0 million. During the three months ended March 31, 2022, the Company also wrote-off $1.2 million of aged receivables that were previously fully reserved. As of March 31, 2022, the balance of receivables related to health insurance and EAP organizations was $6.0 million and the revenue reserves against these receivables was $4.7 million, of this amount $3.4 million relates to aged balances for periods prior to 2022.

*Deferred Revenue*

The Company records deferred revenue when cash payments are received in advance of the Company’s performance obligation to provide services. As of March 31, 2021, deferred revenue related mainly to the Company’s consumer subscription business. Deferred revenue as of March 31, 2022 was $6.0 million ($7.2 million as of December 31, 2021). The Company recognizes deferred revenues as revenues in the statement of operations once performance obligations have been performed and satisfied. The Company expects to satisfy the majority of its performance obligations associated with deferred revenue within one year or less.

11

*Contract Costs*

The Company elected to use the practical expedient to recognize the incremental costs of obtaining contracts as an expense when incurred if the amortization period of the assets that the Company otherwise would have recognized is one year or less.

**NOTE 4. FAIR VALUE MEASUREMENT**

The carrying value of the Company’s cash equivalents, accounts receivable, other current assets, accounts payable, and accrued liabilities approximate fair value because of the relatively short-term nature of the underlying assets. The Company’s Private Placement Warrants are carried at fair value with changes in fair value recognized in earnings each period.

The Private Placement Warrants acquired in connection with the consummation of the Business Combination and the closing of the Forward Purchase Agreement with the HEC Fund are accounted for as liabilities in accordance with ASC 815-40 and are presented within warrant liabilities in the accompanying condensed consolidated balance sheets. The warrant liabilities are measured at fair value at inception and on a recurring basis, with changes in fair value presented within financial (income) expense, net in the condensed consolidated statement of operations.

The Private Placement Warrants were valued using the Black-Scholes-Merton Model, which is considered to be a Level 3 fair value measurement. The primary unobservable input utilized in determining the fair value of the Private Placement Warrants is the expected volatility of the Company’s common stock. The expected volatility of the Company’s common stock was estimated to be approximately 68.8% and 67.8% as of March 31, 2022 and December 31, 2021, respectively. For the three months ended March 31, 2022, the Company had gains related to the revaluation of the Private Placement Warrants of $0.9 million.

The following table presents information about the Company’s liabilities that are measured at fair value on a recurring basis at March 31, 2022 and December 31, 2021 and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value:

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |  |  |
| *(in thousands)* |  | **Level** |  | **March 31, 2022** | |  |  | **December 31, 2021** | |  |
| Liabilities: |  |  |  | (unaudited) | |  |  |  | |  |
| Warrant liability – Private Placement Warrants |  | 3 |  | $ | 3,195 |  |  | $ | 4,070 |  |

The following table presents the changes in the fair value of warrant liabilities during the three months ended March 31, 2022:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  |  |  |  |  |
| *(in thousands)* |  | **Private Placement** | |  |
| Balance at December 31, 2021 |  | $ | 4,070 |  |
| Change in value |  |  | (875 | ) |
| Balance at March 31, 2022 (unaudited) |  | $ | 3,195 |  |

In connection with the consummation of the Business Combination, the Company also acquired Public Warrants from HEC and also issued equity warrants to certain consultants. The Company determined these warrants met the criteria to be classified as equity in accordance with ASC 815-40. The Company valued these warrants using the instrument’s publicly listed trading price on the date of acquisition or issuance, where applicable, and included in additional paid-in capital within stockholder’s deficit. This is considered to be a non-recurring Level 1 measurement due to the use of an observable market quote in an active market.

**NOTE 5. COMMITMENTS AND CONTINGENT LIABILITIES**

*Lease commitments*

The Company does not currently have any leases with terms in excess of 12 months. Since terminating our prior office lease in New York City in August 2020, the Company has an immaterial short-term sublease for office space in New York City. The Company currently has no permanent physical office space and the majority of our employees are working remotely.

The Company has limited operations outside the United States. The Company has one foreign subsidiary located in Israel which leases its operating facilities under a month-to-month operating lease agreement.

12

The Company elected the short-term lease recognition exemption for all leases with a term shorter than 12 months. This means that for those leases, the Company does not recognize ROU assets or lease liabilities, including not recognizing ROU assets or lease liabilities for existing short-term leases of those assets in transition, but recognizes lease expenses over the lease term on a straight-line basis. The Company also elected the practical expedient to not separate lease and non-lease components for all of the Company’s leases.

Rent expenses under the Company’s short-term operating leases for the three months ended March 31, 2022 was $0.1 million (insignificant for the three months ended March 31, 2021).

*Litigation*

The Company is and may in the future be involved in various legal proceedings arising from the normal course of business activities. Although the results of litigation and claims cannot be predicted with certainty, currently, the Company believes that the likelihood of any material adverse impact on the Company’s consolidated results of operations, cash flows or our financial position for any such litigation or claims is remote. Regardless of the outcome, litigation can have an adverse impact on the Company because of the costs to defend lawsuits, diversion of management resources and other factors.

In January 2022, the Company and certain of its current and former officers and directors were named as defendants in a soon to be consolidated securities class action complaint currently listed in the United States District Court for the Southern District of New York (the “Securities Actions”) under the case headings: (1) Baron v. Talkspace et al., No. 22-cv-00163 (S.D.N.Y.) and (2) Valdez v. Talkspace et al., No. 22-cv-00840 (S.D.N.Y.). The Securities Actions asserted violations of sections 10(b), 14(a) and 20(a) of the Securities Exchange Act of 1934 and SEC Rule 14a-9 promulgated thereunder. The Securities Actions generally relate to public disclosures and statements by the Company in connection with the Business Combination. The complaints seek, among other things, damages on behalf of all members of the proposed class. The Court is currently considering a lead plaintiff(s) for the consolidated case.

The Company is not able to predict the outcome of these lawsuits, nor can it predict the amount of time and expense that will be required to resolve the lawsuits. The Company believes that the lawsuits are without merit and intends to vigorously defend against them.

In addition to the foregoing, from time-to-time, the Company is party to various legal proceedings, claims and litigation that arise in the normal course of business. In the opinion of management, the ultimate outcome of these matters will not have a material adverse effect on the Company’s financial position, results of operations or cash flows. Accruals for loss contingencies are recorded when a loss is probable, and the amount of such loss can be reasonably estimated.

*Warranties and Indemnification*

The Company’s arrangements generally include certain provisions for indemnifying clients against liabilities if there is a breach of a Client’s data or if the Company’s service infringes a third party’s intellectual property rights. To date, the Company has not incurred any material costs as a result of such indemnifications.

The Company has also agreed to indemnify its directors and executive officers for costs associated with any fees, expenses, judgments, fines and settlement amounts incurred by any of these persons in any action or proceeding to which any of those persons is, or is threatened to be, made a party by reason of the person’s service as a director or officer, including any action by the Company, arising out of that person’s services as a director or officer or that person’s services provided to any other company or enterprise at the Company’s request. The Company maintains director and officer liability insurance coverage that would generally enable it to recover a portion of any future amounts paid. The Company may also be subject to indemnification obligations by law with respect to the actions of its employees under certain circumstances and in certain jurisdictions.

**NOTE 6. CAPITAL STOCK**

The Company’s authorized capital stock consists of (a) 1,000,000,000 shares of common stock, par value $0.0001 per share; and (b) 100,000,000 shares of preferred stock, par value $0.0001 per share. As of March 31, 2022, there were 155,104,655 shares of common stock issued and outstanding (152,862,447 as of December 31, 2021). As of March 31, 2022 and December 31, 2021, there were no shares of preferred stock issued or outstanding.

13

**NOTE 7. SHARE-BASED COMPENSATION**

The Company adopted the 2014 Stock Incentive Plan (the “2014 Plan”) pursuant to which incentive and nonqualified stock options and stock purchase rights to purchase the Company’s common stock may be granted to officers, employees, directors, consultants and service providers.

In connection with the closing of the Business Combination, the Company adopted the 2021 Incentive Award Plan (the “2021 Plan”) under which the Company may grant cash and equity incentive awards to eligible service providers in order to attract, motivate and retain the talent. In connection with the effectiveness of the 2021 Plan, no further awards will be granted under the 2014 Plan. Employees, consultants and directors of the Company, and employees and consultants of its subsidiaries, are eligible to receive awards under the 2021 Plan.

The 2021 Plan is administered by the Company’s board of directors, which may delegate its duties and responsibilities to one or more committees of the Company’s directors and/or officers (referred to collectively as the “plan administrator”), subject to the limitations imposed under the 2021 Plan, Section 16 of the Securities Exchange Act of 1934, as amended, stock exchange rules and other applicable laws. The plan administrator has the authority to take all actions and make all determinations under the 2021 Plan, to interpret the 2021 Plan and award agreements and to adopt, amend and repeal rules for the administration of the 2021 Plan as it deems advisable. The plan administrator also has the authority to determine which eligible service providers receive awards, grant awards and set the terms and conditions of all awards under the 2021 Plan, including any vesting and vesting acceleration provisions, subject to the conditions and limitations in the 2021 Plan.

The maximum number of shares of Talkspace common stock that may be issued pursuant to the exercise of incentive stock options granted under the 2021 Plan is 100,000,000. The aggregate share limit under the 2021 Plan will be subject to an annual increase on the first day of each calendar year beginning January 1, 2022 and ending on and including January 1, 2031 by a number of shares equal to the lesser of (i) a number equal to 5% of the aggregate number of shares of Talkspace common stock outstanding on the final day of the immediately preceding calendar year and (ii) such smaller number of shares of Talkspace common stock as is determined by the Talkspace board of directors. An aggregate of 11,995,601 shares of Talkspace common stock are available for issuance under the 2021 Plan as of March 31, 2022.

In connection with the closing of the Business Combination, the Company also adopted the 2021 Employee Stock Purchase Plan (the “2021 ESPP”) under which employees of Talkspace and its participating subsidiaries are provided with the opportunity to purchase Talkspace common stock at a discount through accumulated payroll deductions during successive offering periods.

The 2021 ESPP is administered by the compensation committee of the Company’s board of directors (referred to collectively as the “plan administrator”). The plan administrator has the authority to take all actions and make all determinations under the 2021 ESPP, to interpret the 2021 ESPP and to adopt, amend and repeal rules for the administration of the 2021 ESPP as it deems advisable. In addition, the number of shares of common stock available for issuance under the ESPP will be annually increased on January 1 of each calendar year beginning in 2022 and ending in 2031, by an amount equal to the lesser of (i) 1% of the aggregate number of shares of Talkspace common stock outstanding on the final day of the immediately preceding calendar year and (ii) such smaller number of shares of Talkspace common stock as determined by the Talkspace board of directors. The maximum number of shares of Talkspace common stock that may be granted under the 2021 ESPP is 50,000,000. An aggregate of 4,573,602 shares of Talkspace common stock are available for issuance under the 2021 ESPP as of March 31, 2022.

All stock-based awards are measured based on the grant date fair value and are generally recognized on a straight-line basis in the Company’s condensed consolidated statement of operations over the period during which the employee is required to perform services in exchange for the award (generally requiring a four-year vesting period).

14

*Stock Options*

Stock options issued under the Plans generally vest over a four-year period and are exercisable a maximum period of ten years. A summary of the Company’s stock option activity under the 2014 Plan and the 2021 Plan for the three months ended March 31, 2022 is as follows:

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  | **Three Months Ended March 31, 2022** | | | | | | | | | | | | | |  |
|  |  | **Number of options** | |  |  | **Weighted average exercise price** | |  |  | **Weighted average remaining contractual term (in years)** | |  |  | **Aggregate intrinsic value (1)** *(in thousands)* | |  |
| Outstanding at the beginning of the period |  |  | 19,494,202 |  |  | $ | 1.95 |  |  |  | 6.88 |  |  | $ | 19,214 |  |
| Granted |  |  | 1,552,395 |  |  | $ | 1.61 |  |  |  | |  |  |  | |  |
| Exercised |  |  | (2,164,870 | ) |  | $ | 0.95 |  |  |  | |  |  |  | |  |
| Forfeited |  |  | (426,122 | ) |  | $ | 5.06 |  |  |  | |  |  |  | |  |
| Outstanding at the end of the period |  |  | 18,455,605 |  |  | $ | 1.97 |  |  |  | 7.15 |  |  | $ | 14,220 |  |
| Exercisable at the end of the period |  |  | 13,432,414 |  |  | $ | 0.86 |  |  |  | 5.92 |  |  | $ | 13,623 |  |

(1) The aggregate intrinsic value of options outstanding and options exercisable at end of the period does not include 4,779,271 and 1,366,014 options that are out of the money, respectively.

The weighted average grant-date fair value of stock options granted to employees during the three months ended March 31, 2022 and 2021 was $1.06 and $7.00, respectively.

As of March 31, 2022, there was $16.2 million of total unrecognized compensation cost related to non-vested options that are expected to be recognized over a period of up to 4 years.

*Restricted Stock Units*

The Company began issuing restricted stock units (“RSUs”) to certain employees and directors of the Company in the fourth quarter of 2021 under the 2021 plan. These RSUs typically vest over a four-year period.

The following table summarizes the activity for RSUs for the three months ended March 31, 2022:

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |
|  |  | **Three months ended March 31, 2022** | | | | | |  |
|  |  | **Number of restricted stock units** | |  |  | **Weighted average grant-date fair value** | |  |
| Nonvested at beginning of the period |  |  | 2,330,094 |  |  | $ | 3.58 |  |
| Granted |  |  | 3,452,961 |  |  | $ | 1.61 |  |
| Vested |  |  | (116,613 | ) |  | $ | 3.58 |  |
| Forfeited |  |  | (215,518 | ) |  | $ | 3.33 |  |
| Nonvested at end of the period |  |  | 5,450,924 |  |  | $ | 2.35 |  |

The fair value as of the respective vesting dates of RSUs that vested during three months ended March 31, 2022 was $0.2 million. As of March 31, 2022, there was $12.4 million of total unrecognized compensation cost related to non-vested RSUs that are expected to be recognized over a period of up to 3.9 years.

The following table sets forth the total stock-based compensation expense related to stock options and restricted stock units included in the respective components of operating expenses in the condensed consolidated statements of operations:

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |
|  |  | **Three Months Ended March 31,** | | | | | |  |
| *(in thousands)* |  | **2022** | |  |  | **2021** | |  |
| Research and development, net |  | $ | 546 |  |  | $ | 172 |  |
| Clinical Operations |  |  | 122 |  |  |  | 71 |  |
| Sales and Marketing |  |  | 777 |  |  |  | 877 |  |
| General and administrative |  |  | 923 |  |  |  | 393 |  |
| Total stock-based compensation expense |  | $ | 2,368 |  |  | $ | 1,513 |  |

15

**NOTE 8. NET LOSS PER SHARE**

The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders for the periods presented:

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |
|  |  | **Three Months Ended March 31,** | | | | | |  |
| *(in thousands, except share and per share data)* |  | **2022** | |  |  | **2021** | |  |
| Net loss |  | $ | 20,360 |  |  | $ | 12,738 |  |
|  |  |  | |  |  |  | |  |
| Weighted-average shares used to compute net loss per share,      basic and diluted (1) |  |  | 154,083,443 |  |  |  | 13,762,205 |  |
|  |  |  | |  |  |  | |  |
| Net loss per share, basic and diluted (1) |  | $ | 0.13 |  |  | $ | 0.93 |  |

(1) Prior period results have been adjusted to reflect the exchange of Old Talkspace’s common stock for Talkspace’s common stock at an exchange ratio of approximately 1.134140 in June 2021 as a result of the Business Combination.

For the three months ended March 31, 2022, the following were excluded from the calculation of diluted income per share since each would have had an anti-dilutive effect given the Company’s net loss: 18,455,605 stock options, 5,450,924 restricted stock units, 12,780,000 private placement warrants and 21,350,000 public warrants to purchase the Company’s common stock.

For the three months ended March 31, 2021, the following were excluded from the calculation of diluted loss per share since each would have had an anti-dilutive effect given the Company’s net loss: 94,582,550 shares of convertible preferred stock, 20,631,735 stock options, 60,000 warrants to the Company’s common stock and 50,881 warrants to the Company’s series D convertible preferred stock.

**NOTE 9. TAXES ON INCOME**

As a result of the Company’s history of net operating losses (“NOL”), the Company has provided for a full valuation allowance against its deferred tax assets for assets that are not expected to be realized.

The main reconciling item between the statutory tax rate of the Company and the effective tax rate is the recognition of valuation allowance in respect of deferred taxes relating to accumulated net operating losses carried forward due to the uncertainty of the realization of such deferred taxes.

**NOTE 10. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES**

Accrued expenses and other current liabilities are comprised of the following:

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |
| *(in thousands)* |  | **March 31, 2022** | |  |  | **December 31, 2021** | |  |
| Employee compensation |  | $ | 3,135 |  |  | $ | 5,988 |  |
| User acquisition |  |  | 2,791 |  |  |  | 2,680 |  |
| Professional fees |  |  | 1,096 |  |  |  | 1,303 |  |
| Other |  |  | 3,212 |  |  |  | 2,591 |  |
| Accrued expenses and other current liabilities |  | $ | 10,234 |  |  | $ | 12,562 |  |

16

**NOTE 11. SUBSEQUENT EVENTS**

The Company’s wholly owned subsidiaries, Talkspace LLC and Talkspace Network LLC are in the process of entering into various management service agreements (“MSAs”) with Talkspace Provider Network, PA (“TPN”), a Texas professional association entity, as part of the transition of the Company’s structure with respect to its relationships with healthcare providers in response to its expansion of service offerings to include telepsychiatry services provided through licensed physicians. TPN is then contracting with the Company’s affiliated professional entities and physicians, therapists, and other licensed professionals for clinical and professional services provided to the Company’s members. The Company believes the transition to a structure where it operates under various MSAs with TPN, or an entity authorized by state law to contract with our affiliated professionals to delivery teletherapy services to our members, will better ensure the Company is able to comply with additional regulatory requirements, including the corporate practice of medicine and fee-splitting laws, that are necessarily implicated by engaging in telehealth care that can only be delivered by physicians.

In April 2022, the Company transitioned its provider network to TPN. The Company is continuing to transition its current agreements with its clients, members and other business partners to TPN or an affiliated professional entity, where applicable.

TPN is wholly-owned by an independent Texas-licensed physician. The Company has the power to direct the activities of TPN and the other authorized entities in each state that most significantly impact TPN’s and such other authorized entities’ economic performance as well as have the obligation to absorb significant losses and receive the benefits of TPN and the authorized entities. The Company does not believe this transition will have a material financial impact on its operations.

17

**Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.**

*Unless the context otherwise requires, all references in this section to as “Talkspace,” the “Company,” “we,” “us” or “our” refer to the business of Talkspace, Inc. and its subsidiaries.*

*The following discussion and analysis of our financial condition and results of operations should be read together with the financial statements and the related notes contained in this Quarterly Report and the financial statements and related notes contained in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2021. This discussion contains forward-looking statements that reflect our plans, estimates, and beliefs that involve risks and uncertainties. As a result of many factors, such as those discussed in Part I, Item 1A, “Risk Factors” of the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and “Forward-Looking Statements” sections and elsewhere in this Quarterly Report, our actual results may differ materially from those anticipated in these forward-looking statements.*

**Overview**

As a healthcare company enabled by a purpose-built technology platform, Talkspace offers convenient and affordable access to a fully-credentialed network of highly qualified providers. We are a leading virtual behavioral health company and, since Talkspace’s founding in 2012, we have connected millions of patients, who we refer to as our members, with licensed mental health providers across a wide and growing spectrum of care through virtual counseling, psychotherapy and psychiatry. We created a purpose-built platform to address the vast, unmet and growing demand for mental health services of our members, serving our business-to-consumer (“B2C”) channel, comprised of individual consumers who subscribe directly to our platform, and our business-to-business (“B2B”) channel, comprised of large enterprise clients such as Google and Expedia and large health plans and employee assistance programs (“health plan clients”) such as Aetna, Cigna, Premera and Optum (collectively, our “clients”), who offer their employees and insured members access to our platform while their employer is under an active contract with Talkspace, or at in-network reimbursement rates, where applicable.

As of March 31, 2022, we had over 64,000 active members receiving care through our B2C and B2B channels, including approximately 22,200 B2C active members, and approximately 76.5 million B2B eligible lives. We consider members “active” (i) in the case of our B2C members, commencing on the date such member initiates contact with a provider on our platform until the term of their monthly, quarterly or bi-annual subscription plan expires, unless terminated early, and (ii) in the case of our B2B members, if such members have engaged on our platform during the preceding 25 days, such as sending a text, video or audio message to, or participating in a video call with, a provider, completing a satisfaction or progress report survey or signing up for our platform. While a growth in active members typically highlights strong engagement with our members, not all active members are associated with revenue in that particular period. We consider B2B lives “eligible” if such persons are eligible to receive treatment on the Talkspace platform, in the case of our enterprise clients, while their employer is under an active contract with Talkspace, or, in the case of health plan clients, at an agreed upon reimbursement rate through insurance under an employee assistance program or other network behavioral health paid benefit program. There may be instances where a person may be covered through multiple solutions, typically through behavioral health plans and employee assistance programs. In these instances, the person is counted each time they are covered in the B2B eligible lives calculation, which may cause this amount to reflect a higher number of members than we actually serve. For the three months ended March 31, 2022, our clinicians completed 90,600 B2B sessions related to members covered under our health plan clients, as compared to 53,900 completed B2B sessions for the three months ended March 31, 2021.

The behavioral health market has traditionally been underserved for a number of reasons, including as a result of inadequate access, a limited universe of qualified providers, high cost and social stigma. We believe virtual is the ideal modality for mental health treatment because it removes or reduces these burdens associated with traditional face-to-face mental health services by improving convenience through 24/7 access to our platform, providing more accessible entry level price points, and reducing associated stigmas by promoting transparency, increasing ease of access and preserving privacy. Our platform connects consumers in need, including many of whom have never had an opportunity to benefit from high-quality behavioral healthcare, with experienced providers across all 50 U.S. states.

Through our psychotherapy offerings, our licensed therapists and counselors treat mental health conditions in over 21 specializations, such as depression, anxiety, trauma and other human challenges. Through our psychiatry offerings, our board-certified psychiatrists and prescription-eligible nurse practitioners treat a higher acuity patient demographic, including those who may have pharmacological needs. Like the traditional face-to-face models, Talkspace providers are able to treat a wide range of mental health conditions, such as schizophrenia-spectrum disorders, bipolar disorders and depression, including through prescription medication and management from psychiatrists, up and until the point that the provider, in their discretion, feels it prudent to refer the member to a face-to-face psychiatrist to address potential needs for “controlled substances” under the federal Controlled Substances Act, which generally prohibits the prescribing and dispensing of controlled substances via telehealth without performing an in-person examination.

18

While optimizing consumers’ access to care, we believe our platform also provides benefits to providers through expanded reach, steady access to member leads, reduced administrative burdens, more efficient time utilization and data-driven insights. These features, together with continuous training and professional growth opportunities we offer, empower providers to deliver what we believe will enable an enhanced care journey, higher member lifetime engagement, meaningful outcomes and greater margins when compared to face-to-face treatment.

**Operating Segments**

We operate our business in a single segment and as one reporting unit, which is how our chief operating decision maker (who is our interim chief executive officer) reviews financial performance and allocates resources.

**Key Business Metrics**

We monitor the following key metrics to help us evaluate our business, identify trends affecting our business, formulate business plans and make strategic decisions. We believe the following metrics are useful in evaluating our business:

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |
|  |  | **Three Months Ended March 31,** | | | | | |  |
| *(in thousands except number of health plan and enterprise clients or otherwise indicated)* |  | **2022** | |  |  | **2021** | |  |
| Number of B2C active members at period end |  |  | 22.2 |  |  |  | 33.6 |  |
| Number of B2B eligible lives at period end *(in millions)* |  |  | 76.5 |  |  |  | 49.5 |  |
| Number of completed B2B sessions |  |  | 90.6 |  |  |  | 53.9 |  |
| Number of health plan clients at period end |  |  | 16 |  |  |  | 10 |  |
| Number of enterprise clients at period end |  |  | 189 |  |  |  | 91 |  |
| Total number of active members at period end |  |  | 64.5 |  |  |  | 58.7 |  |

*Active Members:* We consider members “active” (i) in the case of our B2C members, commencing on the date such member initiates contact with a provider on our platform until the term of their monthly, quarterly or bi-annual subscription plan expires, unless terminated early, and (ii) in the case of our B2B members, if such members have engaged on our platform during the preceding 25 days, such as sending a text, video or audio message to, or participating in a video call with, a provider, completing a satisfaction or progress report survey or signing up for our platform. While a growth in active members typically highlights strong engagement with our members, not all active members are associated with revenue in that particular period.

*B2B Eligible Lives:* We consider B2B lives “eligible” if such persons are eligible to receive treatment on the Talkspace platform, in the case of our enterprise clients, while their employer is under an active contract with Talkspace, or, in the case of health plan clients, at an agreed upon reimbursement rate through insurance under an employee assistance program or other network behavioral health paid benefit program. There may be instances where a person may be covered through multiple solutions, typically through behavioral health plans and employee assistance programs. In these instances, the person is counted each time they are covered in the B2B eligible lives calculation, which may cause this amount to reflect a higher number of members than we actually serve.

**Non-GAAP Financial Measures**

In addition to our financial results determined in accordance with GAAP, we believe adjusted EBITDA, a non-GAAP measure, is useful in evaluating our operating performance. We use adjusted EBITDA to evaluate our ongoing operations and for internal planning and forecasting purposes. We believe that this non-GAAP financial measure, when taken together with the corresponding GAAP financial measures, provides meaningful supplemental information regarding our performance by excluding certain items that may not be indicative of our business, results of operations or outlook. We believe that the use of adjusted EBITDA is helpful to our investors as it is a metric used by management in assessing the health of our business and our operating performance. However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. In addition, other companies, including companies in our industry, may calculate similarly titled non-GAAP measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of our non-GAAP financial measure as a tool for comparison. A reconciliation is provided below for this non-GAAP financial measure to net loss, the most directly comparable financial measure stated in accordance with GAAP. Investors are encouraged to review our GAAP financial measure and the reconciliation of our non-GAAP financial measure to its most directly comparable GAAP financial measure, and not to rely on any single financial measure to evaluate our business.

19

***Adjusted EBITDA***

Adjusted EBITDA is a key performance measure that our management uses to assess our operating performance. Because adjusted EBITDA facilitates internal comparisons of our historical operating performance on a more consistent basis, we use this measure for business planning purposes and in evaluating acquisition opportunities.

We calculate adjusted EBITDA as net loss adjusted to exclude (i) interest and other expenses (income), net, (ii) tax expense, (iii) depreciation and amortization, (iv) stock-based compensation expense and (v) certain non-recurring expenses, where applicable

The following table presents a reconciliation of adjusted EBITDA from the most comparable GAAP measure, net loss for the three months ended March 31, 2022 and 2021:

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |
|  | **Three Months Ended March 31,** | | | | | |  |
| *(in thousands)* | **2022** | |  |  | **2021** | |  |
| Net loss | $ | (20,360 | ) |  | $ | (12,738 | ) |
| Add: |  | |  |  |  | |  |
| Depreciation and amortization |  | 429 |  |  |  | 462 |  |
| Financial (income) expense, net (1) |  | (869 | ) |  |  | 173 |  |
| Taxes on income |  | 21 |  |  |  | 8 |  |
| Stock-based compensation |  | 2,368 |  |  |  | 1,513 |  |
| Adjusted EBITDA | $ | (18,411 | ) |  | $ | (10,582 | ) |

(1) For the three months ended March 31, 2022, financial (income) expense, net, primarily consisted of $0.9 million in gains resulting from the revaluation of warrant liabilities. For the three months ended March 31, 2021, financial (income) expense, net, primarily consisted of $0.2 million in losses resulting from the revaluation of warrant liabilities.

Some of the limitations of adjusted EBITDA include (i) adjusted EBITDA does not properly reflect capital commitments to be paid in the future and (ii) although depreciation and amortization are non-cash charges, the underlying assets may need to be replaced and adjusted EBITDA does not reflect these capital expenditures. Our adjusted EBITDA may not be comparable to similarly titled measures of other companies because they may not calculate adjusted EBITDA in the same manner as we calculate the measure, limiting its usefulness as a comparative measure. In evaluating adjusted EBITDA, you should be aware that in the future we will incur expenses similar to the adjustments described herein. Our presentation of adjusted EBITDA should not be construed as an inference that our future results will be unaffected by these expenses or any unusual or non-recurring items. Adjusted EBITDA should not be considered as an alternative to loss before income taxes, net loss, loss per share, or any other performance measures derived in accordance with U.S. GAAP. When evaluating our performance, you should consider adjusted EBITDA alongside other financial performance measures, including our net loss and other GAAP results.

**Components of Results of Operations**

***Revenues***

We generate revenues from the sale of monthly, quarterly, bi-annual and annual membership subscriptions to our therapy platform as well as supplementary a la carte offerings, payments from members and their respective insurance companies and annually contracted platform access fees paid to us by our enterprise clients for the delivery of therapy services to their members or employees. We recognize B2C member subscription revenues ratably over the subscription period, beginning when therapy services commence. B2C members may cancel at any time and will receive a pro-rata refund for the subscription price.

We recognize contracted revenue from our enterprise clients from the commencement of their contracted term through the annual period based primarily on a per-member-per month model. We recognize revenues from services provided to insured members at a point in time, as virtual therapy session is rendered. Revenue is recognized in an amount that reflects the consideration that is expected in exchange for the service. Contracts with our enterprise clients are for one or more years with the ability to provide 60 days advance notice prior to termination at each year mark during the term. On occasion and depending on the client, we allow a 60 or 90 day intra-year termination notice but only after the client has completed the first year of service.

Revenue growth is generated from increasing our eligible covered lives through contracting with enterprise clients and health plans, and increasing membership subscriptions.

20

***Cost of Revenues***

Cost of revenues is comprised of therapist payments and hosting costs. Cost of revenues is largely driven by the size of our provider network that is required to service the growth of our customer base, in addition to the growth of our health plan and enterprise clients.

We designed our business model and our provider network to be scalable and to leverage a hybrid model of both employee providers and independently contracted providers to support multiple growth scenarios. The compensation paid to our independently contracted providers is variable, and the amount paid to a provider is generally based on the amount of time committed by such provider to our members. In addition, our network supervisors have broad authority to approve the payment of incentive bonuses to providers with certain licenses during periods of higher demand for providers with such licenses. For our employee providers, they receive a fixed-salary and discretionary bonuses, where applicable.

While we expect increased investments to support accelerated growth and the required investment to scale our provider network, we also expect increased efficiencies and economies of scale. Our cost of revenues as a percentage of revenues is expected to fluctuate from period to period depending on the interplay of these aforementioned factors.

Total employee provider headcount was 290 as of March 31, 2022, as compared to 102 as of March 31, 2021.

***Operating Expenses***

Operating expenses consist of research and development, clinical operations, sales and marketing, and general and administrative expenses.

Total corporate employee headcount was 222 as of March 31, 2022, as compared to 164 as of March 31, 2021.

*Research and Development Expenses*

Research and development expenses include personnel and related expenses for software development and engineering, information technology infrastructure, security and privacy compliance and product development (inclusive of stock-based compensation for our research and development employees), third-party services and contractors related to research and development, information technology, software-related costs, and cost savings related to the application of research grant proceeds.

We expect research and development expenses will increase on an absolute dollar basis as we continue to grow our platform and product offerings; however, the anticipated corresponding future revenue growth is expected to result in lower research and development expenses as a percentage of revenue.

*Clinical Operations Expenses*

Clinical operations expenses are associated with the management of our provider network of therapists. Such costs are comprised of costs related to recruiting, onboarding, credentialing, training and ongoing quality assurance activities (inclusive of stock-based compensation for our clinical operations employees), costs of third-party services and contractors related to recruiting and training and software-related costs.

We expect clinical operations expenses will increase on an absolute dollar basis as we continue to grow our provider network and product offerings; however, the anticipated corresponding future revenue growth is expected to result in lower clinical operations expenses as a percentage of revenue.

21

*Sales and Marketing Expenses*

Sales expenses consist primarily of employee-related expenses, including salaries, benefits, commissions, travel and stock-based compensation costs for our employees engaged in sales and account management.We expect our sales expenses to increase as we continue to invest in the expansion of our health plan and enterprise business. We expect to hire additional sales personnel and related account management personnel to properly service our increasing client base, to develop additional growth opportunities within existing clients and to develop new market opportunities.

Marketing expenses consist primarily of advertising and marketing expenses for consumer acquisition and engagement, as well as personnel costs, including salaries, benefits, bonuses, stock-based compensation expense for marketing employees, third-party services and contractors. Marketing expenses also include third-party software subscription services, third-party independent research, participation in trade shows, brand messaging and costs of communications materials that are produced for our clients to generate greater awareness and utilization of our platform among our health plan and enterprise clients.

Consumer marketing expenses are primarily driven by investments to grow and retain our consumer base and may fluctuate as a percentage of our total revenue from period to period due to the timing and extent of our advertising and marketing expenses.

*General and Administrative Expenses*

General and administrative expenses consist primarily of personnel costs, including salaries, benefits, bonuses and stock-based compensation expense for our executive, finance, accounting, legal and human resources functions, as well as professional fees, occupancy costs, and other general overhead costs. We expect to incur additional general and administrative expenses in compliance, legal, investor relations, director’s and officer’s insurance, and professional services related to our compliance and reporting obligations as a public company.We also anticipate that as we continue to grow as a company our general and administrative expenses will increase on an absolute dollar basis. However, we expect our general and administrative expenses to decrease as a percentage of our total revenue over the next several years.

*Financial (income) expense, net*

Financial (income) expense, net includes the impact from (i) non-cash changes in the fair value of our warrant liabilities, (ii) issuance costs related to our warrant liabilities, (iii) interest earned on cash equivalents deposited in our bank accounts and (iv) other financial expenses in connection with bank charges.

*Taxes on income*

Our taxes on income consists primarily of foreign income taxes related to income generated by our subsidiary organized under the laws of Israel. If we expand the scale of our international business activities, any changes in the U.S. and foreign taxation of such activities may increase our overall provision for income taxes in the future.

We have a full valuation allowance for our U.S. deferred tax assets, including federal and state NOLs. We expect to maintain this valuation allowance until it becomes more likely than not that the benefit of our federal and state deferred tax assets will be realized through expected future taxable income in the United States.

22

**Results of Operations**

The following table presents the results of operations for the three months ended March 31, 2022 and 2021 and the dollar and percentage change between the respective periods:

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  | **Three Months Ended March 31,** | | | | | |  |  | **Variance** | | | | | |  |
|  |  | **2022** | |  |  | **2021** | |  |  | **$** | |  |  | **%** | |  |
| *(in thousands, except percentages, share and per share data)* | |  | | | | | | | | | | | | | |  |
| Consumer revenue |  | $ | 17,260 |  |  | $ | 18,564 |  |  | $ | (1,304 | ) |  |  | (7.0 | ) |
| Commercial revenue |  |  | 12,890 |  |  |  | 8,593 |  |  |  | 4,297 |  |  |  | 50.0 |  |
| Total revenue |  |  | 30,150 |  |  |  | 27,157 |  |  |  | 2,993 |  |  |  | 11.0 |  |
| Cost of revenues |  |  | 15,129 |  |  |  | 9,814 |  |  |  | 5,315 |  |  |  | 54.2 |  |
| Gross profit |  |  | 15,021 |  |  |  | 17,343 |  |  |  | (2,322 | ) |  |  | (13.4 | ) |
| Operating expenses: |  |  | |  |  |  | |  |  |  | |  |  |  | |  |
| Research and development, net |  |  | 5,035 |  |  |  | 2,964 |  |  |  | 2,071 |  |  |  | 69.9 |  |
| Clinical operations |  |  | 1,776 |  |  |  | 2,077 |  |  |  | (301 | ) |  |  | (14.5 | ) |
| Sales and marketing |  |  | 21,408 |  |  |  | 22,251 |  |  |  | (843 | ) |  |  | (3.8 | ) |
| General and administrative |  |  | 8,010 |  |  |  | 2,608 |  |  |  | 5,402 |  |  | \* | |  |
| Total operating expenses |  |  | 36,229 |  |  |  | 29,900 |  |  |  | 6,329 |  |  |  | 21.2 |  |
| Operating loss |  |  | 21,208 |  |  |  | 12,557 |  |  |  | 8,651 |  |  |  | 68.9 |  |
| Financial (income) expense, net |  |  | (869 | ) |  |  | 173 |  |  |  | (1,042 | ) |  | \* | |  |
| Loss before taxes on income |  |  | 20,339 |  |  |  | 12,730 |  |  |  | 7,609 |  |  |  | 59.8 |  |
| Taxes on income |  |  | 21 |  |  |  | 8 |  |  |  | 13 |  |  | \* | |  |
| Net loss |  | $ | 20,360 |  |  | $ | 12,738 |  |  | $ | 7,622 |  |  |  | 59.8 |  |
| Net loss per share (1): | |  | |  |  |  | |  |  |  | |  |  |  | |  |
| *Basic and Diluted* |  | $ | 0.13 |  |  | $ | 0.93 |  |  | $ | (0.79 | ) |  |  | (85.7 | ) |
| Weighted average number of common shares (1): | |  | |  |  |  | |  |  |  | |  |  |  | |  |
| *Basic and Diluted* |  |  | 154,083,443 |  |  |  | 13,762,205 |  |  |  | |  |  |  | |  |

\* Percentage not meaningful.

(1) Prior period results have been adjusted to reflect the exchange of Old Talkspace’s common stock for Talkspace’s common stock at an exchange ratio of approximately 1.134140 in June 2021 as a result of the Business Combination.

**Revenues.** Revenues increased by $3.0 million, or 11.0% to $30.2 million for the three months ended March 31, 2022 from $27.2 million for the three months ended March 31, 2021. The increase was principally due to a 50% growth in B2B revenue driven by an increase in covered lives from health plan clients and new enterprise clients, and a higher number of completed B2B sessions, partially offset by higher revenue reserves on receivables from our existing health plan clients. Enterprise client contracts increased by 98 clients, or 107.7%, to 189 clients as of March 31, 2022 from 91 clients as of March 31, 2021. This increase in the number of enterprise clients increased revenue by $2.4 million, or 72.1%, to $5.7 million for the three months ended March 31, 2022 from $3.3 million for the three months ended March 31, 2021. Revenue, net of reserves, from our health plan clients increased by $1.9 million, or 36.3%, to $7.2 million for the three months ended March 31, 2022 from $5.3 million for the three months ended March 31, 2021. During the three months ended March 31, 2022, the Company recorded an increase in revenue reserves of $1.0 million related to receivables from its health plan clients. B2C member subscriptions revenue decreased by $1.3 million, or 7.0%, to $17.3 million for the three months ended March 31, 2022 from $18.6 million for the three months ended March 31, 2021 due in part to reduced marketing spend, partially offset by a one-time $0.5 million non-cash reversal in deferred revenue associated with customers no longer active on the Company’s platform.

We believe that the appeal of our technology platform, the quality of our providers and the cost of our services will continue to represent the primary drivers of revenue growth from B2B clients and B2C members.

**Costs of revenues.** Cost of revenues increased by $5.3 million, or 54.2%, to $15.1 million for the three months ended March 31, 2022 from $9.8 million for the three months ended March 31, 2021, primarily due to costs associated with an increase of employee providers on our platform and higher therapist compensation expense.

23

**Gross profit*.*** Gross profit decreased by $2.3 million, or 13.4%, to $15.0 million for the three months ended March 31, 2022 from $17.3 million for the three months ended March 31, 2021. This decrease was primarily due to higher cost of revenues due to an increase of providers on our platform to support our increased demand and higher therapist compensation expense, partially offset by the 11.0% increase in revenues. Gross margin (calculated as gross profit as a percentage of revenues) was 49.8% for the three months ended March 31, 2022, compared to 63.9% during the three months ended March 31, 2021. The decrease in gross margin was due primarily to a revenue shift to our B2B business, higher revenue reserves recorded related to our health plan clients and higher therapist compensation expense during the three months ended March 31, 2022.

**Research and development expenses*.*** Research and development expenses increased by approximately $2.1 million, or 69.9%, to $5.0 million for the three months ended March 31, 2022 from $3.0 million for the three months ended March 31, 2021. This was primarily due to an increase in employee-related costs, inclusive of non-cash stock compensation expense.

**Clinical operations expenses*.*** Clinical operations expenses decreased by $0.3 million, or 14.5% to $1.8 million for the three months ended March 31, 2022 from $2.1 million for the three months ended March 31, 2021. This was primarily due to a decrease in provider recruitment costs, partially offset by an increase in employee-related costs, inclusive of non-cash stock compensation expense.

**Sales and marketing expenses*.*** Sales and marketing expenses decreased by $0.8 million, or 3.8%, to $21.4 million for the three months ended March 31, 2022 from $22.3 million for the three months ended March 31, 2021. The decrease in sales and marketing expenses primarily consisted of a decrease in direct marketing and promotional costs, partially offset by an increase in employee-related costs, inclusive of non-cash stock compensation expense.

**General and administrative expenses.** General and administrative expenses increased by $5.4 million to $8.0 million for the three months ended March 31, 2022 from $2.6 million for the three months ended March 31, 2021. This increase was driven primarily by an increase in employee-related costs, inclusive of non-cash stock compensation expense, and an increase in insurance costs and consulting and professional fees.

**Financial (income) expense, net*.*** Financial income, net was $0.9 million for the three months ended March 31, 2022, compared to financial expense, net of $0.2 million for the three months ended March 31, 2021. The change in financial (income) expense, net was driven primarily by non-cash gains resulting from the revaluation of warrant liabilities during the three months ended March 31, 2022, compared to non-cash losses resulting from the revaluation of warrant liabilities during the three months ended March 31, 2021.

**Liquidity and Capital Resources**

As of March 31, 2022, we had $184.1 million of cash and cash equivalents, which were held to finance our operations and support a variety of growth initiatives and investments ($198.3 million as of December 31, 2021). We had no debt as of March 31, 2022 or December 31, 2021 and expect to generate operating losses for the foreseeable future.

Our primary cash needs are to fund operating activities and invest in technology development. Our future capital requirements will depend on many factors including our growth rate, contract renewal activity, the timing and extent of investments to support product development efforts, our expansion of sales and marketing activities, the introduction of new and enhanced service offerings, and the continuing market acceptance of virtual behavioral services. Additionally, we may in the future enter into arrangements to acquire or invest in complementary businesses, services and technologies.

We currently anticipate to be able to fund our cash needs for at least the next twelve months using available cash and cash equivalent balances as of March 31, 2022. However, in the future we may still require additional capital to respond to technological advancements, competitive dynamics or technologies, customer demands, business opportunities, challenges, acquisitions or unforeseen circumstances and we may determine to engage in equity or debt financings or enter into credit facilities for other reasons. We may not be able to timely secure additional debt or equity financing on favorable terms, or at all. If we raise additional funds through the issuance of equity or convertible debt or other equity-linked securities, our existing stockholders could experience significant dilution. Any debt financing obtained by us in the future could involve restrictive covenants relating to our capital raising activities and other financial and operational matters, which may make it more difficult for us to obtain additional capital and to pursue business opportunities, including potential acquisitions. If we are unable to obtain adequate financing or financing on terms satisfactory to us, when we require it, our ability to continue to grow or support our business and to respond to business challenges could be significantly limited.

24

***Cash Flows from Operating, Investing and Financing Activities***

The following table presents the summary condensed consolidated cash flow information for the periods presented:

***Cash Flows***

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |
|  |  | **Three Months Ended March 31,** | | | | | |  |
|  |  | **2022** | |  |  | **2021** | |  |
| *(in thousands)* |  |  | | | | | |  |
| Net cash used in operating activities |  | $ | (15,146 | ) |  | $ | (3,879 | ) |
| Net cash used in investing activities |  |  | (88 | ) |  |  | (319 | ) |
| Net cash provided by financing activities |  |  | 1,505 |  |  |  | 722 |  |
| Net decrease in cash and cash equivalents |  | $ | (13,729 | ) |  | $ | (3,476 | ) |

***Operating Activities***

Net cash used in operating activities was $15.1 million and $3.9 million for the three months ended March 31, 2022 and 2021, respectively. The increase in net cash used in operating activities was driven primarily by the negative impact from a higher net loss during the current-year period and favorable timing of payments on our accounts payable balances during the same prior-year period, partially offset by the favorable timing on collections of receivables during the current-year period. The higher net loss for the three months ended March 31, 2022 was driven primarily by higher general and administrative expenses and higher cost of revenues.

***Investing Activities***

Net cash used in investing activities was $0.1 million for the three months ended March 31, 2022, compared to $0.3 million in net cash provided by investing activities for the three months ended March 31, 2021. The change was driven primarily by a decrease in the purchases of computer equipment and software during the three months ended March 31, 2022 compared to the three months ended March 31, 2021.

***Financing Activities***

Net cash provided by financing activities was $1.5 million and $0.7 million for the three months ended March 31, 2022 and 2021, respectively. The increase was primarily driven by higher proceeds from the exercise of stock options, partially offset by payments for employee taxes withheld related to vested stock-based awards.

**Contractual Obligations, Commitments and Contingencies**

As of March 31, 2022, we did not have any short-term or long-term debt, capital lease obligations, long-term operating lease obligations, or significant long-term liabilities.

Our commercial contract arrangements generally include certain provisions for indemnifying clients against liabilities if there is a breach of a client’s data or if our service infringes a third party’s intellectual property rights. To date, we have not incurred any material costs as a result of such indemnifications.

We have also agreed to indemnify our officers and directors for costs associated with any fees, expenses, judgments, fines and settlement amounts incurred by any of these persons in any action or proceeding to which any of those persons is, or is threatened to be, made a party by reason of the person’s service as a director or officer, including any action by us, arising out of that person’s services as our director or officer or that person’s services provided to any other company or enterprise at our request. We maintain director and officer liability insurance coverage that would generally enable us to recover a portion of any future amounts paid. We may also be subject to indemnification obligations by law with respect to the actions of our employees under certain circumstances and in certain jurisdictions.

**Off-Balance Sheet Arrangements**

We do not invest in any off-balance sheet vehicles that provide liquidity, capital resources, market or credit risk support, or engage in any activities that expose us to any liability that is not reflected in our condensed consolidated financial statements.

25

**Critical Accounting Policies and Estimates**

The Company’s condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. Reference is also made to the Company’s consolidated financial statements and notes thereto found in its Annual Report on Form 10-K for the year ended December 31, 2021.

The Company’s accounting policies are essential to understanding and interpreting the financial results reported on the condensed consolidated financial statements. The significant accounting policies used in the preparation of the Company’s consolidated financial statements are summarized in Note 2 to those statements and the notes thereto found in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021. Certain of those policies are considered to be particularly important to the presentation of the Company's financial results because they require management to make difficult, complex or subjective judgments, often as a result of matters that are inherently uncertain.

During the three months ended March 31, 2022, there were no material changes to matters discussed under the heading “Critical Accounting Policies and Estimates” in Part II, Item 7 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.

**Recent Accounting Pronouncements**

Information regarding recent accounting developments and their impact on our results can be found in “Part I, Item 1. Financial Statements – Note 2 – Significant Accounting Policies” of this Quarterly Report.

**Item 3. Quantitative and Qualitative Disclosures About Market Risk.**

During the three months ended March 31, 2022, there were no material changes to the information contained in Part II, Item 7A of the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.

26

**Item 4. Controls and Procedures.**

***Limitations on Effectiveness of Disclosure Controls and Procedures***

In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of the disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.

***Evaluation of Disclosure Controls and Procedures***

Our management, with the participation of our principal executive officer and principal financial officer, evaluated, as of the end of the period covered by this Quarterly Report, the effectiveness of our disclosure controls and procedures (as that term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based on that evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were not effective at the reasonable assurance level as of March 31, 2022 due to the material weaknesses in our internal control over financial reporting described below.

***Material Weaknesses***

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that a reasonable possibility exists that a material misstatement of our annual or interim financial statements could not be prevented or detected on a timely basis. We have identified material weaknesses in our controls related to the following (a) the aggregation of open control deficiencies across the Company’s financial reporting processes because the controls were not fully designed and operating effectively, (b) not fully designing, implementing and monitoring general information technology controls in the areas of user access and program change-management for systems supporting all of the Company’s internal control processes and (c) our controls on accounting for complex financial instruments such as warrants, did not operate effectively to appropriately apply the provisions of ASC 815-40, resulting in the failure to prevent a material error in our accounting for warrants and the resulting restatement of our previously issued financial statements.

In addition, on April 12, 2021, the Acting Director of the Division of Corporation Finance and Acting Chief Accountant of the SEC together issued a statement (the “SEC Statement”) regarding the accounting and reporting considerations for warrants issued by special purpose acquisition companies entitled “Staff Statement on Accounting and Reporting Considerations for Warrants Issued by Special Purpose Acquisition Companies (“SPACs”). Specifically, the SEC Statement focused on certain settlement terms and provisions related to certain tender offers following a business combination, which terms are similar to those contained in the Warrant Agreement governing our warrants and the HEC Forward Purchase Agreement. Following the issuance of the SEC Statement, on May 4, 2021, HEC concluded that it was appropriate to restate its previously issued audited financial statements as of December 31, 2020 and for the period from February 6, 2020 (inception) through December 31, 2020, as well as its financial data as of June 11, 2020, and as part of such process, HEC identified a material weakness in its internal control over financial reporting. As the accounting acquirer in the Business Combination, we inherited this material weakness and the warrants.

In light of these material weaknesses, we performed additional analysis as deemed necessary to ensure that our financial statements were prepared in accordance with U.S. generally accepted accounting principles. Accordingly, management believes that the financial statements included in this Quarterly Report present fairly in all material respects our financial position, results of operations and cash flows for the periods presented.

***Remediation Activities***

We currently are implementing several actions, as described below, to remediate the material weaknesses described in this Item 4. Management is committed to ensuring that our internal controls over financial reporting are designed and operating effectively.

*Financial Reporting*

We continue to make progress on our automated and manual business process controls, including reports generated from these IT systems, that are dependent upon the completeness and accuracy of information from the affected ITGC material weakness. We are leveraging these improvements in the design of our future state processes and controls within our new enterprise resource planning (“ERP”) system, which is expected to go live during the second half of 2022. Our remediation plan includes, but is not limited to:

27

•

Frequent communications between our Audit Committee and management regarding our financial reporting and internal control environment;

•

The planned expansion of the finance, accounting, reporting and information technology teams through the addition of experienced and qualified resources;

•

The planned improvement of the process and controls in the determination of the appropriate accounting and classification of our financial instruments and key agreements;

•

Delivery of additional internal controls training, as well as policy and control standardization where possible;

•

Re-designed internal controls processes as part of our Sarbanes-Oxley program to drive accountability and efficiency;

•

Instituted monthly review of financial statements to evaluate results, observe adherence to policies and agree on necessary actions;

•

Engaged outside resources to assist with the design and implementation of a risk-based internal controls plan, enhance process documentation, provide company-wide training, and help with management's self-assessment and testing of internal controls

*Information Technology General Controls (“ITGCs”)*

We continue to make progress in advancing foundational elements of our ITGCs as it relates to financial reporting. We are leveraging these foundational elements in the design of our future state processes and controls within our new ERP system. Our remediation plan includes, but is not limited to:

•

Implementing new, relevant IT systems related to our revenue processes and financial reporting;

•

Implementing improved IT change management policies and procedures, control activities, and tools impacting financial reporting to ensure changes affecting financial IT applications are identified, authorized, tested, and implemented appropriately;

•

Implementing improved processes for requesting, authorizing, and reviewing user access to key systems which impact our financial reporting, including identifying access to roles where manual business process controls may be required;

•

Implementing appropriate segregation of duties in relevant systems that impact internal control over financial reporting;

•

Increasing resources dedicated to monitoring ITGCs related to financial reporting to ensure compliance with policies and procedures; and

•

Implementing additional training to ensure a clear understanding of risk assessment and monitoring activities related to automated processes and IT systems and ITGCs related to financial reporting.

*Complex accounting requirements (such as warrants)*

We intend to address this material weakness by enhancing our processes to identify and appropriately apply applicable accounting requirements to better evaluate our research and understanding of the nuances of the complex accounting standards that apply to our financial statements. We intend to provide enhanced access to accounting literature, research materials and documents and increased communication among our personnel and third-party professionals with whom we consult regarding complex accounting applications. We have also retained the services of a valuation expert to assist in valuation analysis of our warrants on a quarterly basis.

When fully implemented and operational, we believe the controls we have designed or plan to design will remediate the control deficiencies that have led to the material weaknesses we have identified and strengthen our internal controls over financial reporting.

The material weaknesses will not be considered remediated until the applicable controls operate for a sufficient period of time and management has concluded, through testing, that these controls are operating effectively.

28

***Changes in Internal Control over Financial Reporting***

Other than as described above, there were no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) during the three months ended March 31, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

29

**PART II—OTHER INFORMATION**

**Item 1. Legal Proceedings.**

From time-to-time, we are party to various legal proceedings, claims and litigation that arise in the normal course of business. In the opinion of management, the ultimate outcome of these matters will not have a material adverse effect on our financial position, results of operations or cash flows. See Note 5, “Commitments and Contingencies,” for further details.

**Item 1a. Risk Factors.**

In addition to the other information set forth in this Quarterly Report, you should carefully consider the factors discussed under Part I, Item 1A. “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021. These factors could materially adversely affect our business, financial condition, liquidity, results of operations and capital position, and could cause our actual results to differ materially from our historical results or the results contemplated by any forward-looking statements contained in this Quarterly Report. During the three months ended March 31, 2022, there were no material changes to the information contained in Part I, Item 1A of the Company's Annual Report on Form 10-K for the year ended December 31, 2021.

30

**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.**

Not applicable.

**Item 3. Defaults Upon Senior Securities.**

None.

**Item 4. Mine Safety Disclosures.**

Not applicable.

**Item 5. Other Information.**

None.

31

**Item 6. Exhibits.**

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  | **Incorporated by Reference** | | | | | | |  | **Filed/** |
| **Exhibit**  **Number** |  | **Exhibit Description** |  | **Form** |  | **File No.** |  | **Exhibit** |  | **Filing**  **Date** |  | **Furnished**  **Herewith** |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
| [2.1](https://www.sec.gov/Archives/edgar/data/1803901/000119312521025013/d119648ds4.htm#rom119648_45) |  | [Agreement and Plan of Merger, dated as of January 12, 2021, by and among Hudson Executive Investment Corp., Tailwind Merger Sub I, Inc., Tailwind Merger Sub II, LLC, and Groop Internet Platform, Inc. (d/b/a Talkspace).](https://www.sec.gov/Archives/edgar/data/1803901/000119312521025013/d119648ds4.htm) |  | S-4 |  | 333-252638 |  | 2.1 |  | 2/2/21 |  |  |
| [3.1](https://www.sec.gov/Archives/edgar/data/1803901/000119312521197385/d182715dex31.htm) |  | [Second Amended and Restated Certificate of Incorporation of Talkspace, Inc.](https://www.sec.gov/Archives/edgar/data/1803901/000119312521197385/d182715dex31.htm) |  | 8-K/A |  | 001-39314 |  | 3.1 |  | 6/23/21 |  |  |
| [3.2](https://www.sec.gov/Archives/edgar/data/1803901/000119312521197385/d182715dex32.htm) |  | [Bylaws of Talkspace, Inc.](https://www.sec.gov/Archives/edgar/data/1803901/000119312521197385/d182715dex32.htm) |  | 8-K/A |  | 001-39314 |  | 3.2 |  | 6/23/21 |  |  |
| [4.1](https://www.sec.gov/Archives/edgar/data/0001803901/000119312520166711/d937996dex41.htm) |  | [Warrant Agreement, dated as of June 8, 2020, by and between Continental Stock Transfer & Trust Company and Hudson Executive Investment Corp.](https://www.sec.gov/Archives/edgar/data/1803901/000119312520166711/d937996dex41.htm) |  | 8-K |  | 001-39314 |  | 4.1 |  | 6/11/20 |  |  |
| [4.2](https://www.sec.gov/Archives/edgar/data/0001803901/000119312520161434/d846732dex43.htm) |  | [Specimen Warrant Certificate of the Registrant.](https://www.sec.gov/Archives/edgar/data/1803901/000119312520161434/d846732dex43.htm) |  | S-1 |  | 333-238583 |  | 4.3 |  | 6/5/20 |  |  |
| [4.3](https://www.sec.gov/Archives/edgar/data/0001803901/000119312521167533/d119648dex45.htm) |  | [Specimen Common Stock Certificate.](https://www.sec.gov/Archives/edgar/data/1803901/000119312521167533/d119648dex45.htm) |  | S-4 |  | 333-252638 |  | 4.5 |  | 5/20/21 |  |  |
| [31.1](talk-ex31_1.htm) |  | [Certification of Chief Executive Officer pursuant to Rule 13a-14(a)/15d-14(a).](talk-ex31_1.htm) |  |  |  |  |  |  |  |  |  | \* |
| [31.2](talk-ex31_2.htm) |  | [Certification of Chief Financial Officer pursuant to Rule 13a-14(a)/15d-14(a).](talk-ex31_2.htm) |  |  |  |  |  |  |  |  |  | \* |
| [32.1](talk-ex32_1.htm) |  | [Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350.](talk-ex32_1.htm) |  |  |  |  |  |  |  |  |  | \*\* |
| [32.2](talk-ex32_2.htm) |  | [Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350.](talk-ex32_2.htm) |  |  |  |  |  |  |  |  |  | \*\* |
| 101.INS |  | Inline XBRL Instance Document - the instance document does not appear in the Interactive Data file because its XBRL tags are embedded within the Inline XBRL document. |  |  |  |  |  |  |  |  |  | \* |
| 101.SCH |  | Inline XBRL Taxonomy Extension Schema Document. |  |  |  |  |  |  |  |  |  | \* |
| 101.CAL |  | Inline XBRL Taxonomy Extension Calculation Linkbase Document. |  |  |  |  |  |  |  |  |  | \* |
| 101.DEF |  | Inline XBRL Taxonomy Extension Definition Linkbase Document. |  |  |  |  |  |  |  |  |  | \* |
| 101.LAB |  | Inline XBRL Taxonomy Extension Label Linkbase Document. |  |  |  |  |  |  |  |  |  | \* |
| 101.PRE |  | Inline XBRL Taxonomy Extension Presentation Linkbase Document. |  |  |  |  |  |  |  |  |  | \* |
| 104 |  | Cover Page Interactive Data File (as formatted as Inline XBRL and contained in Exhibit 101). |  |  |  |  |  |  |  |  |  | \* |

\* Filed herewith.

\*\* Furnished herewith.

32

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

|  |  |  |  |
| --- | --- | --- | --- |
|  |  |  |  |
|  |  | **Talkspace, Inc.** | |
|  |  |  |  |
| Date: May 5, 2022 |  | By: | /s/ Douglas Braunstein |
|  |  |  | Douglas Braunstein |
|  |  |  | Interim Chief Executive Officer |
|  |  |  |  |
| Date: May 5, 2022 |  | By: | /s/ Jennifer Fulk |
|  |  |  | Jennifer Fulk |
|  |  |  | Chief Financial Officer |

33